Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASN512
- Development stage
- Unknown
- Lead developer
- Jiangsu Aosaikang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASN512 is an orally bioavailable small molecule inhibitor of the Tropomyosin receptor kinase (TRK) family, including TRKA, TRKB, and TRKC. Developed by Jiangsu Aosaikang Pharmaceutical, it is currently in Phase 1 clinical development for the treatment of advanced solid tumors, with a particular focus on salivary gland tumors. The drug is designed to target oncogenic drivers such as NTRK gene fusions, which are prevalent in specific subtypes of salivary gland cancer like secretory carcinoma. By inhibiting the constitutive kinase activity of these fusion proteins, ASN512 aims to block downstream signaling pathways that promote tumor cell proliferation and survival.
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)
Beyond the preview
Go deeper on ASN512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASN512.